Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada.
Support Care Cancer. 2018 Mar;26(Suppl 1):11-17. doi: 10.1007/s00520-018-4115-3. Epub 2018 Mar 19.
Numerous groups have published guidelines for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). The current management of CINV, however, remains suboptimal, due in part to poor adherence to existing antiemetic guidelines. Challenges in clinical trial design have also slowed progress and complicated the selection of optimal antiemetic therapy. In addition, patient-specific characteristics and factors are not included in current CINV guidelines and are an important contributor to an individual's risk for nausea and vomiting. CINV risk prediction algorithms have now emerged and provide the opportunity to individualize antiemetic prophylaxis. Further studies are underway to examine the precise role for risk model-guided antiemetic prophylaxis in patients with cancer.
许多团体已经发布了预防和管理化疗引起的恶心和呕吐（CINV）的指南。然而，由于对现有止吐指南的依从性差，目前对 CINV 的管理仍不尽人意。临床试验设计方面的挑战也阻碍了进展，使最佳止吐治疗的选择变得复杂。此外，目前的 CINV 指南中没有包含患者的具体特征和因素，而这些因素是导致个体恶心和呕吐风险的重要因素。CINV 风险预测算法现已出现，为个体化止吐预防提供了机会。目前正在进行进一步的研究，以探讨风险模型指导的止吐预防在癌症患者中的确切作用。
